Single non-blood-related umbilical cord blood transplantation using a reduced-intensity conditioning regimen for the treatment of severe aplastic anemia
Objective To evaluated the clinical efficacy of a reduced-intensity preconditioning regimen for single non-blood-related umbilical cord blood transplantation(sUCBT)in the treatment of severe aplastic anemia(SAA).Methods The clinical data of 63 patients with SAA who underwent sUCBT from January 2021 to July 2023 at the Department of Hematology of the First Affiliated Hospital of USTC were retrospectively analyzed.Fifty-two patients received total body irradiation/total bone marrow irradiation(TMI)combined with fludarabine or a cyclophosphamide-conditioning regimen(non-rATG group),while 11 patients received rabbit anti-human thymocyte immunoglobulin(rATG)combined with TMI,fludarabine,or the cyclophosphamide-conditioning regimen(rATG group).All patients received cyclosporine A and mycophenolate mofetil for graft-versus-host disease(GVHD)prophylaxis.Complications post-transplantation and long-term survival were compared between the two groups.Results The baseline parameters were balanced between the two groups(P＞0.05).In the rATG group,all patients achieved stem cell engraftment,and in the non-rATG group,five patients had primary graft failure.There was no significant difference in the cumulative incidence of neutrophil engraftment at 42 days after transplantation or platelet engraftment at 60 days between the two groups.The incidence of gradeⅡ-Ⅳ acute GVHD in the rATG group was significantly lower than in the non-rATG group(10.0％vs.46.2％,P=0.032),and the differences in the cumulative incidences of grade Ⅲ/Ⅳ acute GVHD and 1-year chronic GVHD were not statistically significant(P=0.367 and P=0.053,respectively).There were no significant differences in the incidences of pre-engraftment syndrome,bacterial bloodstream infections,cytomegalovirus viremia,or hemorrhagic cystitis between the two groups(P＞0.05 for all).The median follow-up time for surviving patients was 536(61-993)days,and the 1-year transplantation related mortality(TRM)of all patients after transplantation was 13.0％(95％CI 6.7％-24.3％).Among the patients in the non-rATG and rATG groups,15.5％(95％CI 8.1％-28.6％)and 0％(P=0.189),respectively,had mutations.The 1-year overall survival(OS)rate of all patients after transplantation was 87.0％(95％CI 75.7％-93.3％).The 1-year OS rates in the rATG group and non-rATG group after transplantation were 100％and 84.5％,respectively(95％CI 71.4％-91.9％)(P=0.198).Conclusion The preliminary results of sUCBT with a low-dose irradiation-based reduced-intensity conditioning regimen with fludarabine/cyclophosphamide for the treatment of patients with SAA showed good efficacy.Early application of low-dose rATG can reduce the incidence of acute GVHD after transplantation without increasing the risk of implantation failure or infection.
Severe aplastic anemiaAntithymocyte globulinReduced-intensity conditioning,RICUmbilical cord blood
维普
万方数据
